eEF2 Protein
Overview
eEF2 (Eukaryotic Elongation Factor 2) is a GTPase that catalyzes the translocation of peptidyl-tRNA from the A site to the P site of the ribosome during protein synthesis. As a highly conserved protein found in all eukaryotes, eEF2 is essential for maintaining cellular protein production at physiological levels. The protein is encoded by the EEF2 gene located on chromosome 19q13.12 in humans and is expressed ubiquitously across tissues, with particularly high expression in the nervous system. eEF2 is approximately 95 kDa in molecular weight and contains a distinctive post-translational modification known as diphthamide, a unique modified histidine residue that is critical for its catalytic function.
Function/Biology
eEF2 functions as a molecular motor protein that catalyzes the movement of tRNA molecules and mRNA through the ribosome during the elongation phase of translation. The protein binds GTP and hydrolyzes it to GDP while promoting the translocation step—the coordinated movement of peptidyl-tRNA to the P site and the deacylated tRNA to the E site. This process advances the mRNA template by precisely three nucleotides, positioning the next codon in the A site for the incoming aminoacyl-tRNA.
...eEF2 Protein
Overview
eEF2 (Eukaryotic Elongation Factor 2) is a GTPase that catalyzes the translocation of peptidyl-tRNA from the A site to the P site of the ribosome during protein synthesis. As a highly conserved protein found in all eukaryotes, eEF2 is essential for maintaining cellular protein production at physiological levels. The protein is encoded by the EEF2 gene located on chromosome 19q13.12 in humans and is expressed ubiquitously across tissues, with particularly high expression in the nervous system. eEF2 is approximately 95 kDa in molecular weight and contains a distinctive post-translational modification known as diphthamide, a unique modified histidine residue that is critical for its catalytic function.
Function/Biology
eEF2 functions as a molecular motor protein that catalyzes the movement of tRNA molecules and mRNA through the ribosome during the elongation phase of translation. The protein binds GTP and hydrolyzes it to GDP while promoting the translocation step—the coordinated movement of peptidyl-tRNA to the P site and the deacylated tRNA to the E site. This process advances the mRNA template by precisely three nucleotides, positioning the next codon in the A site for the incoming aminoacyl-tRNA.
The diphthamide modification on eEF2 at histidine 715 (in humans) is created through a multi-step enzymatic pathway and serves as a sensitive regulatory site. This modification is essential for proper eEF2 function and can be targeted by toxins such as diphtheria toxin and pseudomonas exotoxin A. eEF2 activity is regulated by phosphorylation through eEF2 kinase (eEF2K), a calcium/calmodulin-dependent protein kinase. Phosphorylation at threonine 56 inactivates eEF2 and reduces translation elongation rates, thereby decreasing protein synthesis during periods of cellular stress or energy limitation.
Neurodegeneration" style="color:#4fc3f7;margin:1.5rem 0 0.6rem;font-size:1.15rem;font-weight:700;border-bottom:2px solid rgba(79,195,247,0.3);padding-bottom:0.3rem">Role in Neurodegeneration
eEF2 dysfunction has been implicated in multiple neurodegenerative diseases through multiple mechanistic pathways. In Alzheimer's disease, reduced eEF2 activity correlates with decreased synthesis of critical synaptic proteins and impaired neuroplasticity. The phosphorylation and inactivation of eEF2 by calcium-dependent kinases occurs excessively in response to abnormal calcium signaling triggered by amyloid-beta accumulation, contributing to synaptic deficits and memory impairment.
In Parkinson's disease and other alpha-synucleinopathies, evidence suggests that misfolded alpha-synuclein aggregates impair the translation machinery, including eEF2 function, leading to insufficient production of proteins necessary for neuronal survival. Similarly, in Huntington's disease, mutant huntingtin protein interferes with translation elongation factor activity, reducing the synthesis of neuroprotective proteins and exacerbating neuronal toxicity.
Molecular Mechanisms
The molecular basis of eEF2 dysfunction in neurodegeneration involves several interconnected mechanisms. Excessive calcium influx through NMDA receptors activates eEF2K, leading to eEF2 phosphorylation and translation inhibition. This initial protective response becomes pathological when sustained chronically, resulting in insufficient protein synthesis for neuronal maintenance and survival.
Additionally, post-translational modifications of eEF2 itself—beyond the diphthamide modification—including oxidation and abnormal phosphorylation patterns, impair its GTPase activity. Interaction with protein aggregates characteristic of neurodegenerative diseases physically obstructs eEF2 function at the ribosomal interface, preventing efficient translocation.
Dysregulation of eEF2K expression and activity amplifies these deficits. Elevated eEF2K expression has been observed in post-mortem Alzheimer's brain tissue, contributing to chronic translation suppression.
Clinical/Research Significance
eEF2 represents an important therapeutic target for neuroprotection. Modulating eEF2K activity through inhibition could maintain translation of pro-survival proteins during neurodegenerative stress. Research using eEF2K inhibitors has shown promise in preventing neuronal death in cell and animal models of Alzheimer's and Parkinson's diseases.
Understanding eEF2 dysregulation provides mechanistic insights into how protein synthesis deficits contribute to neurodegeneration and identifies potential biomarkers for disease progression through measurement of eEF2 phosphorylation status in cerebrospinal fluid or neuronal tissue.
- eEF2 Kinase (eEF2K)
- Diphthamide modification
- Translation elongation machinery
- NMDA receptor signaling
- Amyloid-beta toxicity
- Synaptic protein synthesis
- Post-translational modifications